CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the ...
Fintel on MSN
Baird Upgrades Vor Biopharma (VOR)
Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback